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S162 Oral PresentationsSSI use was 152 (13-981) days. At 6months and 1 year, 63% and 83%
of patients were off all immunosuppressive therapy, respectively.
With a median follow-up of 26 months, cumulative incidence of
chronic GVHD was 10%. Only 3 patients have died with refractory
GVHD. These results extend our previous observations that post-
transplantation Cy is effective single agent strategy for prophylaxis
of acute GVHD with both a low rate of grade III-IV and more
than half of the patients never requiring additional SSI. The limited
use of SSI may be responsible for low infectious rate and excellent
immune reconstitution seen in these patients. This approach also
provides novel platform to facilitate the use of post-transplant immu-
notherapy aimed at reducing relapse.20
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Objective: To evaluate the impact of HLA matching and differ-
ence in matching degree among transplants from unrelated donors
(UD) on different outcomes in chronic lymphocytic leukemia
(CLL).
Materials & Methods: We have analyzed 370 CLL patients who
underwent an allogeneic HSCT reported to the EBMT registry.
There were 280 males (75%) and 90 females with a median age of
53 years (24-69). At transplant, 294 among 317 evaluated patients
had a good performance status (PS) (93%), 43 patients were in CR
(12%), 160 in PR (46%), 44 in SD (13%) and 103 in PD (29%)
among 349 evaluated patients. Two hundred and sixty six patients re-
ceived a reduced intensity conditioning regimen (RIC) and 103
a standard (Std) conditioning; 313 patients received PBSC, 56 BM
and 2 cord blood cells from 198HLA siblings, and 172 unrelated do-
nors (UD).According to the registry, there were 198 HLA siblings,
135matchedUD (MUD) and 37mismatchedUD (MMUD).We fo-
cused on UD and re-analyzed all HLA typings for patients and do-
nors, after classification we found: 31 well matched (10/10, 8/8) in
high resolution), 30 matched in low resolution and 111 mismatched
in high resolution.
We found a high significant difference in term of OS between the
siblings, well & partially matched groups versus low & MMUD
groups (p5 0.002) (figure2). [OS at 3 & 5 years: Siblings: 68.3%
(61.8-75.5) and 57.2% (49.8-65.6); well matched: 60.8% (43.1-85.8)
from 3 to 5 years, low resolution &MMUD: 50.5% (43.1-60.1) and
39.6% (29.5-50.2) respectively]. We observed also a high significant
difference in term of transplant relatedmortality (TRM) between the
same groups (p5 0.0024) (figure4). The multivariate analysis using
Cox model studying age, pre-transplant status, gender, PS, cells
source, ABO compatibility, conditioning and different HLA groups,
showed a significant impact of 3 factors onOS: age [HR5 1.04 (1.02-
1.6) p5 0.001], PS [HR5 2.75 (1.5-5.1) p5 0.001] and HLA
MMUD+Low resolution group [HR5 1.43 (1.01-2.01) p5 0.04].
The same factors were also highly significant in multivariate analysis
in term of TRM (age: HR5 1.04 (1.001-1.07) p5 0.0033; PS:
HR5 2.47 (1.1-5.4) p5 0.009 and HLA MMUD group: HR5 1.8
(1.07-3.37) p5 0.004.21
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This retrospective report assessed the outcome of 629 patients
aged$60 years and who received RIC allo-SCT, with a special em-
phasis on the comparison of the outcome of patients aged 60-65 and
patients aged .65 y.
The median age for the whole cohort was 62 (range, 60-71) y. 378
patients (55%) had a myeloid malignancy, while 240 (38%) had lym-
phoid malignancies, and 11 (2%) had other diseases. 386 patients
(61%) received allo-SCT from an HLA-matched related donor,
while 199 patients (32%) received the graft from a MUD, and 44
(7%) frommismatched donors. The conditioning regimen consisted
of Fludarabine and Busulfan in 280 cases (44.5%), Fludarabine and
low dose TBI in 150 cases (24%). The remaining 199 patients
(32%) received other so-called RIC regimens.
With a median follow-up of 9 (range, 1-90) m., grade II-IV and
grade III-IV acute GVHD occurred in 29% (n5 182) and 12%
(n5 76) of patients, respectively. Chronic GVHD was observed
in 145 patients (23%; limited: n5 67; extensive: n5 72; unknown
stage: n5 6). 180 patients died of transplant-related causes
(TRM: 29%). The estimates of overall survival (OS) at 1 and 2
years were 57% (95%CI, 53-62%) and 47% (95%CI, 42-52%),
respectively.
In order to assess the applicability of RIC allo-SCT to the older
age group, we compared the outcome of patients aged from 60 to
65 y. (n5 516) and those aged .65 y. (n5 113). Except for age, in
univariate analysis, these 2 groups were not statistically different in
terms of demographic, disease or transplant characteristics. The
incidences of grade II-IV and grade III-IV acute GVHD were com-
parable between both groups (29% vs. 30%, p5NS; and 12% vs.
12%; p5NS). The TRM incidence was 29% in the younger group
vs. 27% in the older group (p5NS). The estimates of OS at one and
2 years were 58% (95%CI, 53-62%) and 47% (95%CI, 42-52%) in
the younger age group and 55% (95%CI, 44-65%) and 48%
(95%CI, 37-60%) in the older age group (p5NS). In a Cox multi-
variate analysis accounting for all relevant factors, age.65 y. was not
found to be a statistically significant factor associated with worsened
survival.
In all, this data support the use of RIC-allo-SCT in patients.60 y.
Outcome of patients aged.65 y. appears to be comparable to that of
patients aged 60-65 y. Physiologic aging is likely more important
than chronologic aging. With the refinement of comorbidities scor-
ing systems, age per se (at least up to 70 y.) should not be a contrain-
dication to perform RIC allo-SCT.22
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While non-myeloablative conditioning significantly reduces mor-
bidity and mortality after allogeneic hematopoietic cell transplanta-
tion (HCT), the risk of allograft rejection is increased. Persistent
host cells mediate host-vs-graft alloreactivity or occupy niches in
the hematopoietic microenvironment. Here we studied engraftment
and hematopoietic reconstitution in BALB.K mice given non-mye-
loablative radiation and purified hematopoietic stem cells (HSC:
cKIT +Thy1.1loSca1 + Lin-) +/- T cells (TC) from AKR/J donors,
a MHC-identical (H-2 K) model with high barriers to engraftment.
Recipients of pure HSC regularly achieved stable mixed chimerism.
However, if grafts contained CD4 TC (but not CD8 TC) donor
lymphopoiesis was completely abolished in 80% of hosts, even
long-term. This suppression was associated with bone marrow
(BM) lymphopenia (\5% vs .40% after HSC alone), and hypocel-
lularity (median 3.8 vs 13.3 x10^6 cells/2 legs; p5 0.0003) at 2 weeks
post-HCT. B cell reconstitution was the most severely affected (6%
vs 75% of lymphocytes). At this early time point there was expansion
of donor and host CD4 TC, each comprising 6% of BM cells (vs
Oral Presentations S163\1% in mice given HSC), accompanied by a substantial increase of
host NK cells (median 14% vs\1%; 6.3 vs\0.4 x10^5 cells). Donor
CD4 TC in the BM expressed high levels of IFNg (30-50%), which
exceeded IFNg secretion in control groups (3-15%). Similar find-
ings of engraftment failure due to donor CD4 TC were noted
when mice were conditioned with total lymphoid irradiation (TLI:
17240 cGy): while recipients of HSC alone were mixed chimeras
in all lineages, those given HSC +TC failed to engraft with T and
B cells, had only marginal myeloid engraftment, but increased pro-
portions of host NK cells in the PB. We conclude that after non-
myeloablative conditioning transplantation of pure HSC can result
in superior immune reconstitution and donor chimerism as com-
pared to grafts supplemented with CD4 TC. These results are of
broad significance, as it is generally believed that TC augment donor
HSC engraftment. The way in which CD4 TC retard engraftment
appears to be by induction of inflammation within the BMmicroen-
vironment and activation of host lymphoid populations that mediate
resistance. IFNg, which is a known regulator of innate and acquired
immune responses, may be central in activating host CD4 TC,
enhancing NK cell mediated rejection of the graft and/or suppres-
sion of donor hematopoiesis.23
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Introduction:Dendritic cells (DC) are central to the development
of acute graft-versus-host disease (GvHD) following allogeneic he-
matopoietic cell transplantation (alloHCT). Because DC migration
is tightly regulated by the interaction between chemokine receptors
on DC and their ligands, we investigated the relationship between
the severity of acute GvHD and the expression of the chemokine
receptors CCR5 and CCR7 on CD11c+ myeloid and CD11c- plas-
macytoid DC from the peripheral blood of 32 patients post al-
loHCT.
Methods: Peripheral blood was collected twice weekly up to day 100
post transplant. The expression of each chemokine receptor on
CD11c+ and CD11c- DC was calculated using multiparameter
flow cytometry. The percentage of CD11c+ DC expressing a given
receptor was added to the percentage of CD11c- DC expressing
the same receptor to give a maximum score that could vary from
0 to 200%.
Results: Eleven of 32 patients developed moderate to severe acute
GvHD (grade II-IV), the remaining 21 patients developed either
no GvHD or only grade I GvHD. The percentage of DC express-
ing either CCR5 or CCR7 was correlated with the development of
acute GvHD. CCR7 expression was detected in 13 of 32 patients
post-HCT with a median of 2.3% of DC positive (range 0 to
39%). CCR7 expression on DC showed no association with the se-
verity of acute GvHD (p5 1.0). In contrast, higher CCR5 expres-
sion was detected on DC in patients developing grade II-IV
GvHD (median 98.0%, SEM 9.1%) than in those with grade 0-I
GvHD (median 5.2%, SEM 5.1%) p\0.0001. All eleven patients
with grade II-IV GvHD expressed CCR5 at a level of .35% of
myeloid and plasmacytoid DC. Only two of 21 patients with grade
1 GvHD expressed CCR5 at the same level (66% and 94%). Most
importantly, the expression of CCR5 preceded the development of
moderate to severe GvHD in all patients by a median of 19 days
(range 2 to 47 days, SEM 4.3 days). Using a receiver operator
curve analysis, CCR5 expression above 35% demonstrated a sensi-
tivity of 100% and a specificity of 90.5% for predicting grade II-IV
GvHD.
Conclusion:Expression of CCR5 on circulatingDCpost allo-HCT
predicts for the development of moderate to severe GvHD, and de-
tection could allow earlier therapeutic intervention prior to the de-
velopment of clinical GVHD.24
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Using murine models of acute GVHD in which allogeneic bone
marrow cells are transplanted into lethally irradiated hosts, we and
others have shown that donorCD4+CD25+Foxp3+ regulatoryT cells
(Treg) are able to suppress GVHD induced by donor allogeneic con-
ventional T cells (Tcon). The potential clinical use of Treg is limited
by their low number. To overcome this problem, expansion of Treg
has been performed, however, there has not been a head-to-head
comparison of the function of expanded vs. fresh Treg. Highly puri-
fied CD4+CD25+Foxp3+ T cells (.98% purity) were expanded
using anti-CD3/CD28 dynabeads and 1000 U/ml IL-2. Treg cul-
tured for five days expanded up to 13 fold while maintaining high
Foxp3 expression levels (85-90%). The expanded Treg (eTreg)
were evaluated in an in vivo acute GVHD mouse model in direct
comparison with freshly isolatedTreg (fTreg) using a novel biolumi-
nescent imaging assay (BLI) that allowed for quantitative assessment
of Tcon proliferation in addition to traditional metrics of GVHD se-
verity. Expanded Treg were significantly more effective at suppress-
ing the early proliferation of Tcon than an equal number of fTreg
(P\0.0001). On day 6, mice that received Tcon and eTreg had
a mean BLI signal of 1.5106 photons/sec/mouse, four times lower
than the signal of mice receiving Tcon and fTreg (5.8106 photons/
sec/mouse). The difference in potency may be explained by the in-
creased number of eTreg compared to fTreg that were re-isolated
from peripheral lymph nodes (PLN) (40,600 total eTreg/PLN/
mouse vs. 5,200 total fTreg/PLN/mouse) at day 5, suggesting that
expanded Treg arrived and proliferated in PLN faster than the fresh
Treg. However, over time, the eTreg lose their protective capabil-
ities and, in order to suppress GVHD symptoms and improve sur-
vival, a greater number of eTreg were required compared to
fTreg. On day 37, the mean GVHD score for the Tcon alone group
was 8.66 0.74. Fresh Treg added at 1:1 ratio with Tcon decreased
GVHD score to 1.46 0.25 (p\ 0.0001). Ex-vivo expanded Treg
demonstrated a dose-dependent decrease in GVHD score, although
four times more eTreg were needed to obtain a similar reduction in
GVHD score (0.336 0.3, p5 0.0002). Although eTreg are less
potent at suppressing GVHD than fTreg, the greater numbers
achievable by short-term culture makes them viable option for treat-
ment ofGVHD, however, increased ratios of Treg:Tcon are likely to
be required.25
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Background:Graft failure (GF) is a serious and fatal complication
that can occur in up to 30% of Fanconi anemia (FA) patients sub-
mitted to hemaopoietic stem cell transplantation. (HSCT). The
goal of this study was the analysis of risks factors for GF in patients
with FA.
Patient andMethods Between January 1985 and July 2008, 203 pts
with FA were submitted to an HSCT and 168 were evaluable for en-
graftment .Thirty-one had graft failure (group A), while 140pts had
an adequate engraftment (group B). Pts in group A had a longer du-
ration of the disease when compared to pts in group B (40 versus 19
months – p5 0,004) and they were also more transfused (43 versus 8
– p\0,001). Stem cell source: Group A: Bone marrow (BM) 65%
and umbilical cord blood (UCB) 35%. Group B: 85% BM and
15%UCB.Unrelated donors (UD) were used in 68%of pts in group
A and 28% in group B (p\0,001); there were also less compatible
transplant in group A (57 versus 79%- p5 0,01). A de-escalation
dose of cyclophosphamide was used for the majority of pts receiving
a related HSCT while a fludarabine based regimen was used in pts
with UD. GVHD prophylaxis consisted of cyclosporine and metho-
trexate in the majority of pts.
